农夫山泉(09633)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09633 农夫山泉

未开盘 06-17 16:08:37

42.760

-1.300

-2.95%

最高44.380	最低42.620	成交量453.41万
今开44.200	昨收44.060	日振幅3.99%
总市值4,809亿	流通市值2,153亿	总股本112.46亿
成交额1.96亿	换手率0.09%	流通股本50.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09633","market":"HK","secType":"STK","nameCN":"农夫山泉","latestPrice":42.76,"timestamp":1781683717012,"preClose":44.06,"halted":0,"volume":4534098,"delay":0,"changeRate":-0.029505220154335092,"floatShares":5034666400,"shares":11246000000,"eps":1.631376843391998,"marketStatus":"未开盘","change":-1.3,"latestTime":"06-17 16:08:37","open":44.2,"high":44.38,"low":42.62,"amount":196001055,"amplitude":0.039946,"askPrice":42.76,"askSize":92600,"bidPrice":42.74,"bidSize":13200,"shortable":3,"etf":0,"ttmEps":1.631376843391998,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781746200000},"marketStatusCode":0,"adr":0,"listingDate":1599494400000,"exchange":"SEHK","adjPreClose":44.06,"dividendRate":0.026844,"openAndCloseTimeList":[[1781659800000,1781668800000],[1781672400000,1781683200000]],"volumeRatio":0.9527305415311701,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"NFU.HK","impliedVol":0.2963,"impliedVolPercentile":0.2846},"requestUrl":"/m/hq/s/09633","defaultTab":"news","newsList":[{"id":"2644718586","title":"甄鹏到勐库镇调研农夫山泉项目和高标准农田建设情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2644718586","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644718586?lang=zh_cn&edition=full","pubTime":"2026-06-17 13:05","pubTimestamp":1781672700,"startTime":"0","endTime":"0","summary":"6月16日，县委书记甄鹏到勐库镇实地调研农夫山泉项目及高标准农田建设推进情况。甄鹏强调，农夫山泉项目要优化全流程施工方案，细化工序衔接，倒排工期节点，动态统筹调配人力、物料、机械设备，减少工序空档、压缩等待时长，确保项目按期竣工交付，助推当地茶产业提质发展。甄鹏要求，相关责任监管部门要切实履行监管职责，健全项目全过程、常态化督导监管体系，常态化下沉项目一线开展巡查督导。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-17/doc-inicsvwq8957455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09633","LU1981816686.USD","BK1200","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644176204","title":"股市必读：万泰生物（603392）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644176204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644176204?lang=zh_cn&edition=full","pubTime":"2026-06-17 03:30","pubTimestamp":1781638232,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，万泰生物报收于28.9元，上涨1.9%，换手率0.58%，成交量7.39万手，成交额2.12亿元。董秘最新回复投资者： 邱董你好，贵公司的戊肝疫苗已经通过在印度开展临床试验的方式取得获批并已经上市。目前针对低年龄段的二价国免，能保障10年后的宫颈癌患病率下降。公司将持续与相关部门保持紧密沟通。公司九价HPV疫苗的保护效力也已通过III期效力临床试验获得验证，公司始终遵循科学严谨的态度进行市场宣传和信息披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700003317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","BK1200","BK1589","LU1981816686.USD","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643758396","title":"万泰生物：持续探索政企合作等更多元的模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2643758396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643758396?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:15","pubTimestamp":1781601333,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物06月16日在投资者关系平台上答复投资者关心的问题。目前针对低年龄段的二价国免，能保障10年后的宫颈癌患病率下降。公司将持续与相关部门保持紧密沟通。后续会持续探索政企合作等更多元的模式，逐步推广普及方案，全力助力宫颈癌防控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600030148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1200","LU1981816686.USD","603392","09633","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643758330","title":"万泰生物：已搭建起多层次、广覆盖的会议推广体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2643758330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643758330?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:15","pubTimestamp":1781601333,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物06月16日在投资者关系平台上答复投资者关心的问题。目前已搭建起多层次、广覆盖的会议推广体系，从全国性大型学术会议，到省、市、区县级专题会议，再下沉至基层接种点，均完成系统化布局。相关工作有效提升了医疗机构、疾控体系及大众对疫苗接种的认知，唤醒更多适龄女性的接种意识，推动HPV疫苗整体接种率的提升，为宫颈癌防控贡献力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600030147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1589","BK0239","09633","BK1200","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643475836","title":"万泰生物：公司九价HPV疫苗已完成全国31个省、自治区、直辖市（不含港澳台地区）的省级招标准入","url":"https://stock-news.laohu8.com/highlight/detail?id=2643475836","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643475836?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:15","pubTimestamp":1781601313,"startTime":"0","endTime":"0","summary":"公司九价HPV疫苗已完成全国31个省、自治区、直辖市的省级招标准入，具备了面向该地区供应的资格。公司九价HPV疫苗与进口九价HPV疫苗开展的头对头研究结果显示，免疫原性整体非劣效于进口九价HPV疫苗，其中5个型别GMC比值的点值高于1，安全性方面整体表现相当。公司九价HPV疫苗的保护效力也已通过III期效力临床试验获得验证，公司始终遵循科学严谨的态度进行市场宣传和信息披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600030131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1200","159646","09633","BK1589","603392","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642076684","title":"6月11日万泰生物跌6.68%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642076684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642076684?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:23","pubTimestamp":1781166183,"startTime":"0","endTime":"0","summary":"证券之星消息，6月11日万泰生物跌6.68%创60日新低，收盘报28.93元，换手率0.57%，成交量7.2万手，成交额2.11亿元。重仓万泰生物的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100025241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","09633","BK1200","603392","562860","BK1589","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642465246","title":"万泰生物：治疗板块并入公司没有仅以盈利或重磅新药作为单一前置标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642465246","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642465246?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:15","pubTimestamp":1780996524,"startTime":"0","endTime":"0","summary":"养生堂治疗板块并入公司的前提条件是什么？万泰生物聚焦于体外诊断试剂和预防产品的业务领域，治疗性创新药物属于养生堂集团的业务范围。但是也不排除公司在将来合适的时机和养生堂探讨将治疗板块纳入到上市公司内的可能性。治疗板块并入公司没有仅以盈利或重磅新药作为单一前置标准，整合需要综合考量产业协同、资产合规、监管规则、股东会审议等多重条件，兼顾上市公司与全体股东利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK0239","BK1200","09633","603392","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642346510","title":"万泰生物：董事长邱子欣先生此前披露的减持计划已提前终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2642346510","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642346510?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:12","pubTimestamp":1780996330,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：目前邱总减持计划实施情况如何万泰生物回复：您好！董事长邱子欣先生此前披露的减持计划已提前终止，本轮未减持股份，具体内容详见公司于指定信息披露媒体披露的《北京万泰生物药业股份有限公司董事未减持公司股份并提前终止减持计划的公告》（公告编号：2026-026）。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1200","09633","BK1589","BK0239","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642655894","title":"万泰生物：推动业务从服务B端机构向直达C端消费者的模式变革","url":"https://stock-news.laohu8.com/highlight/detail?id=2642655894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642655894?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:54","pubTimestamp":1780995269,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物06月09日在投资者关系平台上答复投资者关心的问题。公司扩编一线销售人员是基于长期主义的战略主动布局，核心逻辑如下：传统疫苗行业高度依赖渠道推广，消费者缺乏主动认知与选择权，本次扩编是公司推动业务从服务B端机构向直达C端消费者的模式变革，目的是做好疫苗科普，建立消费者品牌信任，赋予大众主动选择优质疫苗的权利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","LU1981816686.USD","BK1589","09633","BK1200","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642653394","title":"万泰生物：普惠接种与筛查相结合的模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2642653394","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642653394?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:54","pubTimestamp":1780995255,"startTime":"0","endTime":"0","summary":"期望万泰在普及疫苗的同时进行筛查，确保人民健康！您所倡导的普惠接种与筛查相结合的模式，与公司致力于提升HPV疫苗可及性、助力消除宫颈癌的公共卫生目标高度契合。公司始终高度重视宫颈癌防控的公共卫生价值，持续与各地相关部门保持紧密沟通，积极探索多元模式，逐步推广普及方案，全力助力宫颈癌防控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1200","09633","BK1589","BK0239","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642453463","title":"万泰生物：目前公司九价HPV疫苗的定价为499元/支","url":"https://stock-news.laohu8.com/highlight/detail?id=2642453463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642453463?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:48","pubTimestamp":1780994892,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物06月09日在投资者关系平台上答复投资者关心的问题。目前公司九价HPV疫苗的定价为499元/支，会根据市场情况，必要时进行调整。疫苗接种率的提升受到政策、接种意愿等多种因素影响，公司将持续优化策略，提升HPV疫苗可及性，助力实现消除宫颈癌的公共卫生目标。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633","159646","BK1589","BK1200","LU1981816686.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133222","title":"【券商聚焦】国投证券：油价冲高抬升饮料核心包材PET价格 料饮料企业全年成本端承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133222","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133222?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:26","pubTimestamp":1780536369,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券研究认为，26Q1春节期间大众品礼赠市场强势复苏，叠加春节错期下的“大年”效应，使得礼赠属性强的中小饮料标的业绩好于此前市场预期。25年以来中小饮料企业积极创新，新品推动“健康化、年轻化、功能性”升级，纷纷积极探索二次成长路径。成本方面，美伊冲突导致油价上涨，使得饮料核心包材PET价格大幅走高，尽管部分饮料公司提前锁价，但对大部分饮料企业而言，今年全年成本端仍会承受一定压力。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983000","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PXE","BK1500","IEO","LU0471298777.SGD","09985","BWET","DRIP","OILT","BNO","00291","LU1720050803.USD","DBC","GUSH","USOI","09633","DRLL","LU0359201885.HKD","LU1171460220.USD","USE","01876","OILK","00220","80291","LU0702159343.USD","DBO","IE0008368742.USD","WTIU","OILU","ERX","06186","USL","DBE","00322","LU0228367735.SGD","LU0762542818.HKD","CRHKY","161027","DIG","02319","FTXN","UGA","XES","IXC","PXJ","DUG","OIH","00168","VDE","BK1553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131237673","title":"农夫山泉5月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1131237673","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131237673?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:51","pubTimestamp":1780393900,"startTime":"0","endTime":"0","summary":"农夫山泉股份有限公司于2026年6月2日发布了截至2026年5月31日的证券变动月报表，本期股本结构继续保持稳定，未出现新增发行或回购注销等情况。报告显示，截至2026年5月31日，农夫山泉股份有限公司的法定/注册股本总额为人民币1,124,646,640元。比较上月底数据，本期股本总额及股数均无变动。公告同时显示，公司当月无股权激励计划变动，无新增股份发行、购回或注销事项。本次月报由执行董事及公司秘书韩林攸签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640930315","title":"万泰生物：公司持续拓展多元化预约接种渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2640930315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640930315?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:36","pubTimestamp":1780306580,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：公司领导好:想问一下，腾讯健康疫苗在线预约这么大平台怎么没国产九价可约，公司不推广吗？万泰生物回复：您好！公司持续拓展多元化预约接种渠道。目前腾讯健康预约平台受地域限制，部分地区暂未覆盖，后续公司将进一步丰富线上预约渠道，提升服务可及性。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100026666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","09633","BK1200","BK0239","BK1589","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640370699","title":"万泰生物：2025年戊肝疫苗在印度市场成功获批上市并实现商业化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2640370699","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640370699?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:24","pubTimestamp":1780305866,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物06月01日在投资者关系平台上答复投资者关心的问题。请问戊肝疫苗在印度销售有没有达到公司预期？2025年，公司戊肝疫苗在印度市场成功获批上市并实现商业化落地。依托扎实的临床数据与成熟的质量体系，公司戊肝疫苗获得当地监管机构认可，并通过本地合作伙伴开展多渠道市场推广，重点覆盖高风险人群，持续提升公众认知与接种意愿。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100026201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","603392","BK1200","BK0239","BK1589","LU1981816686.USD","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640080937","title":"万泰生物：已完成泰国和印尼相关协议的签订","url":"https://stock-news.laohu8.com/highlight/detail?id=2640080937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640080937?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:24","pubTimestamp":1780305862,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：邱董你好，请问贵公司已经开始与泰国，印尼启动九价疫苗本土化的工作，是否已经签有协议？是否会公布协议内容。万泰生物回复：您好！公司已完成泰国和印尼相关协议的签订，现阶段公司正与本土合作伙伴稳步协作，合力推进九价HPV疫苗本土化生产相关落地工作。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100026196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","BK1589","BK0239","LU1981816686.USD","09633","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640292937","title":"万泰生物：构建“自主创新+开放合作”双引擎驱动体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2640292937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640292937?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:21","pubTimestamp":1780305675,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物06月01日在投资者关系平台上答复投资者关心的问题。另外关于疫苗管线的研发数量，建议还要增加一些。非常感谢您提出的宝贵建议。公司通过持续推进技术平台的纵深升级与前瞻布局，形成可持续产出重磅产品的技术储备，不断拓展疫苗管线的广度与深度。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100026125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1200","BK1589","BK0239","603392","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640093726","title":"万泰生物：公司海外业务以产品出口为核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2640093726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640093726?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:21","pubTimestamp":1780305673,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：目前公司国外订单或意向客户主要是那方面业务，检测相关产品出货量如何。万泰生物回复：您好！公司海外业务以产品出口为核心，同步推进海外技术转移与本地化合作，持续输出技术与产业化能力，积极参与全球公共卫生建设，助力提升全球疫苗可及性。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100026122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","09633","BK1200","LU1981816686.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640224934","title":"万泰生物(603392.SH)：九价HPV疫苗提交WHO PQ认证申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2640224934","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640224934?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:30","pubTimestamp":1780302613,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司(简称“万泰沧海”)向世界卫生组织(简称“WHO”)提交了公司自主研发的九价人乳头瘤病毒疫苗(大肠埃希菌)(简称“九价HPV疫苗”)预认证(简称“PQ认证”)申请相关资料。九价HPV疫苗为万泰沧海自主研发的预防用生物制品，已于2025年获得国家药品监督管理局颁发的药品注册证书，为我国首款、全球第二款九价HPV疫苗，主要适用于9-45岁女性，覆盖HPV16/18/31/33/45/52/58七种高危型和HPV6/11两种低危型，可预防上述型别人乳头瘤病毒感染引起的相关疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1981816686.USD","159646","09633","603392","BK1200","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640933095","title":"【券商聚焦】中信建投维持农夫山泉(09633)“增持”评级 指其双引擎驱动多品类增势强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2640933095","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640933095?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:56","pubTimestamp":1780293362,"startTime":"0","endTime":"0","summary":"2025年公司包装水逐步复苏，饮料板块保持强劲增长，东方树叶持续高增带动公司产品结构提升，盈利能力屡上台阶，无糖饮料赛道长坡厚雪，公司创新性、健康化产品梯次推出，长期享受健康化红利。面对2026年PET等成本波动，公司表示有信心应对，价格体系、行为方式、管理秩序不变。维持“增持”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MDk5ZmM0NTcxYzk0YjcwOWJkYjI3OTdjNWViYWI0ZTM0MzI3NjM2OTE1MTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDk5ZmM0NTcxYzk0YjcwOWJkYjI3OTdjNWViYWI0ZTM0MzI3NjM2OTE1MTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982639","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09633"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nongfuspring.com","stockEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.0239},{"period":"3month","weight":0.022},{"period":"6month","weight":-0.0757},{"period":"1year","weight":0.1186},{"period":"ytd","weight":-0.0627}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0466},{"period":"6month","weight":-0.0537},{"period":"1year","weight":0.0138},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"农夫山泉股份有限公司是一家主要从事生产及销售包装饮用水及饮料的中国公司。该公司通过五个分部运营。水类产品分部从事制造及销售天然包装饮用水。即饮茶类产品分部从事制造及销售即饮茶。功能饮料产品分部从事制造及销售功能饮料。果汁饮料产品分部从事制造及销售果汁饮料产品。其他产品分部从事制造及销售农产品及其他饮料。该公司主要在国内市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.003567},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.016331},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.07575},{"month":4,"riseRate":0.666667,"avgChangeRate":0.026458},{"month":5,"riseRate":0.666667,"avgChangeRate":0.019912},{"month":6,"riseRate":0.5,"avgChangeRate":-0.023606},{"month":7,"riseRate":0.8,"avgChangeRate":0.01459},{"month":8,"riseRate":0.4,"avgChangeRate":0.006063},{"month":9,"riseRate":0.6,"avgChangeRate":0.047998},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.055387},{"month":11,"riseRate":0.833333,"avgChangeRate":0.094346},{"month":12,"riseRate":0.666667,"avgChangeRate":0.06968}],"exchange":"SEHK","name":"农夫山泉","nameEN":"NONGFU SPRING"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"农夫山泉(09633)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供农夫山泉(09633)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"农夫山泉,09633,农夫山泉股票,农夫山泉股票老虎,农夫山泉股票老虎国际,农夫山泉行情,农夫山泉股票行情,农夫山泉股价,农夫山泉股市,农夫山泉股票价格,农夫山泉股票交易,农夫山泉股票购买,农夫山泉股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"农夫山泉(09633)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供农夫山泉(09633)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}